HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Buckner, C. L. Articles by Lazarchick, J. Search for Related Content PubMed PubMed Citation Articles by Buckner, C. L. Articles by Lazarchick, J.

CD20 Positive T-cell Lymphoma/Leukemia: A Rare Entity with Potential Diagnostic Pitfalls

Address correspondence to John Lazarchick, M.D., Dept. of Pathology & Laboratory Medicine, Medical University of South Carolina, 165 Ashley Avenue, Suite 309, Charleston, SC 29425, USA; tel 843 792 0217; fax 843 792 4811; e-mail lazarj{at}musc.edu.

Mature T-cell neoplasms are relatively uncommon, accounting for approximately 10% of all non-Hodgkin lymphomas.This category of hematopoietic neoplasms is clinically aggressive and shows a poor response to therapy and shortened survival.The antigen CD20 has long been thought to be a specific marker for B-cell lineage and has been used to help differentiate T-cell and B-cell neoplasms. We present two cases of a rare subset of T-cell leukemia/lymphoma having a unique immunophenotype, both being CD20+.The significance of CD20 antigen in T-cell lymphomas is yet to be determined, but may allow treatment with novel therapeutic agents (eg, rituximab, a recombinant anti-CD20 monoclonal antibody).

Keywords: CD20 antigen, lymphoma, leukemia, rituximab